Selected research
Market Structure
Global Humanized Monoclonal Antibody Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Humanized Monoclonal Antibody Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Humanized Monoclonal Antibody Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Humanized Monoclonal Antibody Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Humanized Monoclonal Antibody Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Humanized Monoclonal Antibody Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Humanized Monoclonal Antibody Drugs include Innovent Bio, Takeda, Teva, Sun Pharmaceutical, Johnson & Johnson, Qilu Pharma, Novartis, Merck & Co and Roche, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Humanized Monoclonal Antibody Drugs market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Humanized Monoclonal Antibody Drugs and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Humanized Monoclonal Antibody Drugs revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Humanized Monoclonal Antibody Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.
Humanized Monoclonal Antibody Drugs Segment by Company
Innovent Bio
Takeda
Teva
Sun Pharmaceutical
Johnson & Johnson
Qilu Pharma
Novartis
Merck & Co
Roche
Eli Lilly & Co
Pfizer
Beigene
GlaxoSmithKline
Biogen
AbbVie
AstraZeneca
UCB
Gilead Sciences
Humanized Monoclonal Antibody Drugs Segment by Type
Ixekizumab
Vedolizumab
Risenqizumab
Trastuzumab
Pembrolizumab
Farisimab
Bevacizumab
Orelizumab
Omalizumab
Other
Humanized Monoclonal Antibody Drugs Segment by Application
Cancers
Inflammatory Condition
Autoimmune Diseases
Humanized Monoclonal Antibody Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Humanized Monoclonal Antibody Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Humanized Monoclonal Antibody Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Humanized Monoclonal Antibody Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Humanized Monoclonal Antibody Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Humanized Monoclonal Antibody Drugs industry.
Chapter 3: Detailed analysis of Humanized Monoclonal Antibody Drugs companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Humanized Monoclonal Antibody Drugsrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
List of Tables
Table 1. Global Humanized Monoclonal Antibody Drugs Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032
Table 2. Key Players of Ixekizumab
Table 3. Key Players of Vedolizumab
Table 4. Key Players of Risenqizumab
Table 3. Key Players of Trastuzumab
Table 4. Key Players of Pembrolizumab
Table 5. Key Players of Farisimab
Table 6. Key Players of Bevacizumab
Table 7. Key Players of Orelizumab
Table 8. Key Players of Omalizumab
Table 9. Key Players of Other
Table 10. Global Humanized Monoclonal Antibody Drugs Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032
Table 11. Key Players of Cancers
Table 12. Key Players of Inflammatory Condition
Table 13. Key Players of Autoimmune Diseases
Table 14. Global Humanized Monoclonal Antibody Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032
Table 15. Global Humanized Monoclonal Antibody Drugs Market Size by Region (2021-2026) & (US$ Million)
Table 16. Global Humanized Monoclonal Antibody Drugs Market Share by Region (2021-2026)
Table 17. Global Humanized Monoclonal Antibody Drugs Market Size by Region (2027-2032) & (US$ Million)
Table 18. Global Humanized Monoclonal Antibody Drugs Market Share by Region (2027-2032)
Table 19. Humanized Monoclonal Antibody Drugs Industry Trends
Table 20. Humanized Monoclonal Antibody Drugs Industry Drivers
Table 21. Humanized Monoclonal Antibody Drugs Industry Opportunities and Challenges
Table 22. Humanized Monoclonal Antibody Drugs Industry Restraints
Table 23. Global Humanized Monoclonal Antibody Drugs Revenue by Company (US$ Million) & (2021-2026)
Table 24. Global Humanized Monoclonal Antibody Drugs Revenue Market Share by Company (2021-2026)
Table 25. Global Humanized Monoclonal Antibody Drugs Players Revenue Ranking, 2024 VS 2025 VS 2026
Table 26. Global Humanized Monoclonal Antibody Drugs Key Company Head Office and Area Served
Table 27. Global Humanized Monoclonal Antibody Drugs Company, Product Type & Application
Table 28. Global Humanized Monoclonal Antibody Drugs Company Establishment Date
Table 29. Global Company Market Concentration Ratio (CR5 and HHI)
Table 30. Global Humanized Monoclonal Antibody Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025)
Table 31. Global Humanized Monoclonal Antibody Drugs Market Size by Type 2021 VS 2025 VS 2032 (US$ Million)
Table 32. Global Humanized Monoclonal Antibody Drugs Market Size by Type (2021-2026) & (US$ Million)
Table 33. Global Humanized Monoclonal Antibody Drugs Market Size by Type (2027-2032) & (US$ Million)
Table 34. Global Humanized Monoclonal Antibody Drugs Revenue Market Share by Type (2021-2026)
Table 35. Global Humanized Monoclonal Antibody Drugs Revenue Market Share by Type (2027-2032)
Table 36. Global Humanized Monoclonal Antibody Drugs Market Size by Application 2021 VS 2025 VS 2032 (US$ Million)
Table 37. Global Humanized Monoclonal Antibody Drugs Market Size by Application (2021-2026) & (US$ Million)
Table 38. Global Humanized Monoclonal Antibody Drugs Market Size by Application (2027-2032) & (US$ Million)
Table 39. Global Humanized Monoclonal Antibody Drugs Revenue Market Share by Application (2021-2026)
Table 40. Global Humanized Monoclonal Antibody Drugs Revenue Market Share by Application (2027-2032)
Table 41. Innovent Bio Company Information
Table 42. Innovent Bio Business Overview
Table 43. Innovent Bio Humanized Monoclonal Antibody Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 44. Innovent Bio Humanized Monoclonal Antibody Drugs Product Portfolio
Table 45. Innovent Bio Recent Development
Table 46. Takeda Company Information
Table 47. Takeda Business Overview
Table 48. Takeda Humanized Monoclonal Antibody Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 49. Takeda Humanized Monoclonal Antibody Drugs Product Portfolio
Table 50. Takeda Recent Development
Table 51. Teva Company Information
Table 52. Teva Business Overview
Table 53. Teva Humanized Monoclonal Antibody Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 54. Teva Humanized Monoclonal Antibody Drugs Product Portfolio
Table 55. Teva Recent Development
Table 56. Sun Pharmaceutical Company Information
Table 57. Sun Pharmaceutical Business Overview
Table 58. Sun Pharmaceutical Humanized Monoclonal Antibody Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 59. Sun Pharmaceutical Humanized Monoclonal Antibody Drugs Product Portfolio
Table 60. Sun Pharmaceutical Recent Development
Table 61. Johnson & Johnson Company Information
Table 62. Johnson & Johnson Business Overview
Table 63. Johnson & Johnson Humanized Monoclonal Antibody Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 64. Johnson & Johnson Humanized Monoclonal Antibody Drugs Product Portfolio
Table 65. Johnson & Johnson Recent Development
Table 66. Qilu Pharma Company Information
Table 67. Qilu Pharma Business Overview
Table 68. Qilu Pharma Humanized Monoclonal Antibody Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 69. Qilu Pharma Humanized Monoclonal Antibody Drugs Product Portfolio
Table 70. Qilu Pharma Recent Development
Table 71. Novartis Company Information
Table 72. Novartis Business Overview
Table 73. Novartis Humanized Monoclonal Antibody Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 74. Novartis Humanized Monoclonal Antibody Drugs Product Portfolio
Table 75. Novartis Recent Development
Table 76. Merck & Co Company Information
Table 77. Merck & Co Business Overview
Table 78. Merck & Co Humanized Monoclonal Antibody Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 79. Merck & Co Humanized Monoclonal Antibody Drugs Product Portfolio
Table 80. Merck & Co Recent Development
Table 81. Roche Company Information
Table 82. Roche Business Overview
Table 83. Roche Humanized Monoclonal Antibody Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 84. Roche Humanized Monoclonal Antibody Drugs Product Portfolio
Table 85. Roche Recent Development
Table 86. Eli Lilly & Co Company Information
Table 87. Eli Lilly & Co Business Overview
Table 88. Eli Lilly & Co Humanized Monoclonal Antibody Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 89. Eli Lilly & Co Humanized Monoclonal Antibody Drugs Product Portfolio
Table 90. Eli Lilly & Co Recent Development
Table 91. Pfizer Company Information
Table 92. Pfizer Business Overview
Table 93. Pfizer Humanized Monoclonal Antibody Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 94. Pfizer Humanized Monoclonal Antibody Drugs Product Portfolio
Table 95. Pfizer Recent Development
Table 96. Beigene Company Information
Table 97. Beigene Business Overview
Table 98. Beigene Humanized Monoclonal Antibody Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 99. Beigene Humanized Monoclonal Antibody Drugs Product Portfolio
Table 100. Beigene Recent Development
Table 101. GlaxoSmithKline Company Information
Table 102. GlaxoSmithKline Business Overview
Table 103. GlaxoSmithKline Humanized Monoclonal Antibody Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 104. GlaxoSmithKline Humanized Monoclonal Antibody Drugs Product Portfolio
Table 105. GlaxoSmithKline Recent Development
Table 106. Biogen Company Information
Table 107. Biogen Business Overview
Table 108. Biogen Humanized Monoclonal Antibody Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 109. Biogen Humanized Monoclonal Antibody Drugs Product Portfolio
Table 110. Biogen Recent Development
Table 111. AbbVie Company Information
Table 112. AbbVie Business Overview
Table 113. AbbVie Humanized Monoclonal Antibody Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 114. AbbVie Humanized Monoclonal Antibody Drugs Product Portfolio
Table 115. AbbVie Recent Development
Table 116. AstraZeneca Company Information
Table 117. AstraZeneca Business Overview
Table 118. AstraZeneca Humanized Monoclonal Antibody Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 119. AstraZeneca Humanized Monoclonal Antibody Drugs Product Portfolio
Table 120. AstraZeneca Recent Development
Table 121. UCB Company Information
Table 122. UCB Business Overview
Table 123. UCB Humanized Monoclonal Antibody Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 124. UCB Humanized Monoclonal Antibody Drugs Product Portfolio
Table 125. UCB Recent Development
Table 126. Gilead Sciences Company Information
Table 127. Gilead Sciences Business Overview
Table 128. Gilead Sciences Humanized Monoclonal Antibody Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 129. Gilead Sciences Humanized Monoclonal Antibody Drugs Product Portfolio
Table 130. Gilead Sciences Recent Development
Table 131. North America Humanized Monoclonal Antibody Drugs Market Size by Type (2021-2026) & (US$ Million)
Table 132. North America Humanized Monoclonal Antibody Drugs Market Size by Type (2027-2032) & (US$ Million)
Table 133. North America Humanized Monoclonal Antibody Drugs Market Size by Application (2021-2026) & (US$ Million)
Table 134. North America Humanized Monoclonal Antibody Drugs Market Size by Application (2027-2032) & (US$ Million)
Table 135. North America Humanized Monoclonal Antibody Drugs Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million)
Table 136. North America Humanized Monoclonal Antibody Drugs Market Size by Country (2021-2026)
Table 137. North America Humanized Monoclonal Antibody Drugs Market Size by Country (2027-2032)
Table 138. Europe Humanized Monoclonal Antibody Drugs Market Size by Type (2021-2026) & (US$ Million)
Table 139. Europe Humanized Monoclonal Antibody Drugs Market Size by Type (2027-2032) & (US$ Million)
Table 140. Europe Humanized Monoclonal Antibody Drugs Market Size by Application (2021-2026) & (US$ Million)
Table 141. Europe Humanized Monoclonal Antibody Drugs Market Size by Application (2027-2032) & (US$ Million)
Table 142. Europe Humanized Monoclonal Antibody Drugs Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million)
Table 143. Europe Humanized Monoclonal Antibody Drugs Market Size by Country (2021-2026)
Table 144. Europe Humanized Monoclonal Antibody Drugs Market Size by Country (2027-2032)
Table 145. China Humanized Monoclonal Antibody Drugs Market Size by Type (2021-2026) & (US$ Million)
Table 146. China Humanized Monoclonal Antibody Drugs Market Size by Type (2027-2032) & (US$ Million)
Table 147. China Humanized Monoclonal Antibody Drugs Market Size by Application (2021-2026) & (US$ Million)
Table 148. China Humanized Monoclonal Antibody Drugs Market Size by Application (2027-2032) & (US$ Million)
Table 149. Asia Humanized Monoclonal Antibody Drugs Market Size by Type (2021-2026) & (US$ Million)
Table 150. Asia Humanized Monoclonal Antibody Drugs Market Size by Type (2027-2032) & (US$ Million)
Table 151. Asia Humanized Monoclonal Antibody Drugs Market Size by Application (2021-2026) & (US$ Million)
Table 152. Asia Humanized Monoclonal Antibody Drugs Market Size by Application (2027-2032) & (US$ Million)
Table 153. Asia Humanized Monoclonal Antibody Drugs Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million)
Table 154. Asia Humanized Monoclonal Antibody Drugs Market Size by Country (2021-2026)
Table 155. Asia Humanized Monoclonal Antibody Drugs Market Size by Country (2027-2032)
Table 156. South America, Middle East & Africa Humanized Monoclonal Antibody Drugs Market Size by Type (2021-2026) & (US$ Million)
Table 157. South America, Middle East & Africa Humanized Monoclonal Antibody Drugs Market Size by Type (2027-2032) & (US$ Million)
Table 158. South America, Middle East & Africa Humanized Monoclonal Antibody Drugs Market Size by Application (2021-2026) & (US$ Million)
Table 159. South America, Middle East & Africa Humanized Monoclonal Antibody Drugs Market Size by Application (2027-2032) & (US$ Million)
Table 160. South America, Middle East & Africa Humanized Monoclonal Antibody Drugs Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million)
Table 161. South America, Middle East & Africa Humanized Monoclonal Antibody Drugs Market Size by Country (2021-2026)
Table 162. South America, Middle East & Africa Humanized Monoclonal Antibody Drugs Market Size by Country (2027-2032)
Table 163. Research Programs/Design for This Report
Table 164. Authors List of This Report
Table 165. Secondary Sources
Table 166. Primary Sources
List of Figures
Figure 1. Humanized Monoclonal Antibody Drugs Product Image
Figure 2. Global Humanized Monoclonal Antibody Drugs Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million)
Figure 3. Global Humanized Monoclonal Antibody Drugs Market Share by Type: 2025 VS 2032
Figure 4. Ixekizumab Image
Figure 5. Vedolizumab Image
Figure 6. Risenqizumab Image
Figure 7. Trastuzumab Image
Figure 8. Pembrolizumab Image
Figure 9. Farisimab Image
Figure 10. Bevacizumab Image
Figure 11. Orelizumab Image
Figure 12. Omalizumab Image
Figure 13. Other Image
Figure 14. Global Humanized Monoclonal Antibody Drugs Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million)
Figure 15. Global Humanized Monoclonal Antibody Drugs Market Share by Application: 2025 VS 2032
Figure 16. Cancers Image
Figure 17. Inflammatory Condition Image
Figure 18. Autoimmune Diseases Image
Figure 19. Global Humanized Monoclonal Antibody Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032
Figure 20. Global Humanized Monoclonal Antibody Drugs Market Size (2021-2032) & (US$ Million)
Figure 21. Global Humanized Monoclonal Antibody Drugs Market Share by Region: 2025 VS 2032
Figure 22. Years Considered
Figure 23. Global Humanized Monoclonal Antibody Drugs Market Share by Players in 2025
Figure 24. Global Top 5 and 10 Humanized Monoclonal Antibody Drugs Players Market Share by Revenue in 2025
Figure 25. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 26. Global Humanized Monoclonal Antibody Drugs Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million)
Figure 27. Global Humanized Monoclonal Antibody Drugs Revenue Market Share by Type (2021-2032)
Figure 28. Global Humanized Monoclonal Antibody Drugs Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million)
Figure 29. Global Humanized Monoclonal Antibody Drugs Revenue Market Share by Application (2021-2032)
Figure 30. North America Humanized Monoclonal Antibody Drugs Market Size (2021-2032) & (US$ Million)
Figure 31. North America Humanized Monoclonal Antibody Drugs Market Share by Type (2021-2032)
Figure 32. North America Humanized Monoclonal Antibody Drugs Market Share by Application (2021-2032)
Figure 33. North America Humanized Monoclonal Antibody Drugs Market Share by Country (2021-2032)
Figure 34. United States Humanized Monoclonal Antibody Drugs Market Size (2021-2032) & (US$ Million)
Figure 35. Canada Humanized Monoclonal Antibody Drugs Market Size (2021-2032) & (US$ Million)
Figure 36. Mexico Humanized Monoclonal Antibody Drugs Market Size (2021-2032) & (US$ Million)
Figure 37. Europe Humanized Monoclonal Antibody Drugs Market Size (2021-2032) & (US$ Million)
Figure 38. Europe Humanized Monoclonal Antibody Drugs Market Share by Type (2021-2032)
Figure 39. Europe Humanized Monoclonal Antibody Drugs Market Share by Application (2021-2032)
Figure 40. Europe Humanized Monoclonal Antibody Drugs Market Share by Country (2021-2032)
Figure 41. Germany Humanized Monoclonal Antibody Drugs Market Size (2021-2032) & (US$ Million)
Figure 42. France Humanized Monoclonal Antibody Drugs Market Size (2021-2032) & (US$ Million)
Figure 43. U.K. Humanized Monoclonal Antibody Drugs Market Size (2021-2032) & (US$ Million)
Figure 44. Italy Humanized Monoclonal Antibody Drugs Market Size (2021-2032) & (US$ Million)
Figure 45. Russia Humanized Monoclonal Antibody Drugs Market Size (2021-2032) & (US$ Million)
Figure 46. Nordic Countries Humanized Monoclonal Antibody Drugs Market Size (2021-2032) & (US$ Million)
Figure 47. China Humanized Monoclonal Antibody Drugs Market Size (2021-2032) & (US$ Million)
Figure 48. China Humanized Monoclonal Antibody Drugs Market Share by Type (2021-2032)
Figure 49. China Humanized Monoclonal Antibody Drugs Market Share by Application (2021-2032)
Figure 50. Asia Humanized Monoclonal Antibody Drugs Market Size (2021-2032) & (US$ Million)
Figure 51. Asia Humanized Monoclonal Antibody Drugs Market Share by Type (2021-2032)
Figure 52. Asia Humanized Monoclonal Antibody Drugs Market Share by Application (2021-2032)
Figure 53. Asia Humanized Monoclonal Antibody Drugs Market Share by Country (2021-2032)
Figure 54. Japan Humanized Monoclonal Antibody Drugs Market Size (2021-2032) & (US$ Million)
Figure 55. South Korea Humanized Monoclonal Antibody Drugs Market Size (2021-2032) & (US$ Million)
Figure 56. Taiwan Humanized Monoclonal Antibody Drugs Market Size (2021-2032) & (US$ Million)
Figure 57. Southeast Asia Humanized Monoclonal Antibody Drugs Market Size (2021-2032) & (US$ Million)
Figure 58. India Humanized Monoclonal Antibody Drugs Market Size (2021-2032) & (US$ Million)
Figure 59. Australia Humanized Monoclonal Antibody Drugs Market Size (2021-2032) & (US$ Million)
Figure 60. South America, Middle East & Africa Humanized Monoclonal Antibody Drugs Market Size (2021-2032) & (US$ Million)
Figure 61. South America, Middle East & Africa Humanized Monoclonal Antibody Drugs Market Share by Type (2021-2032)
Figure 62. South America, Middle East & Africa Humanized Monoclonal Antibody Drugs Market Share by Application (2021-2032)
Figure 63. South America, Middle East & Africa Humanized Monoclonal Antibody Drugs Market Share by Country (2021-2032)
Figure 64. Brazil Humanized Monoclonal Antibody Drugs Market Size (2021-2032) & (US$ Million)
Figure 65. South Africa Humanized Monoclonal Antibody Drugs Market Size (2021-2032) & (US$ Million)
Figure 66. Saudi Arabia Humanized Monoclonal Antibody Drugs Market Size (2021-2032) & (US$ Million)
Figure 67. Turkey Humanized Monoclonal Antibody Drugs Market Size (2021-2032) & (US$ Million)
Figure 68. Argentina Humanized Monoclonal Antibody Drugs Market Size (2021-2032) & (US$ Million)
Figure 69. UAE Humanized Monoclonal Antibody Drugs Market Size (2021-2032) & (US$ Million)
Figure 70. Egypt Humanized Monoclonal Antibody Drugs Market Size (2021-2032) & (US$ Million)
Figure 71. Chile Humanized Monoclonal Antibody Drugs Market Size (2021-2032) & (US$ Million)
Figure 72. Research Process
Figure 73. Key Executives Interviewed
Scope & coverage.
Types
- Ixekizumab
- Vedolizumab
- Risenqizumab
- Trastuzumab
- Pembrolizumab
- Farisimab
- Bevacizumab
- Orelizumab
- Omalizumab
- Other
Applications
- Cancers
- Inflammatory Condition
- Autoimmune Diseases
Companies covered
- Innovent Bio
- Takeda
- Teva
- Sun Pharmaceutical
- Johnson & Johnson
- Qilu Pharma
- Novartis
- Merck & Co
- Roche
- Eli Lilly & Co
- Pfizer
- Beigene
- GlaxoSmithKline
- Biogen
- AbbVie
- AstraZeneca
- UCB
- Gilead Sciences
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Humanized Monoclonal Antibody Drugs Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Ixekizumab
- 1.2.3 Vedolizumab
- 1.2.4 Risenqizumab
- 1.2.5 Trastuzumab
- 1.2.6 Pembrolizumab
- 1.2.7 Farisimab
- 1.2.8 Bevacizumab
- 1.2.9 Orelizumab
- 1.2.10 Omalizumab
- 1.2.11 Other
- 1.3 Market Analysis by Application
- 1.3.1 Global Humanized Monoclonal Antibody Drugs Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Cancers
- 1.3.3 Inflammatory Condition
- 1.3.4 Autoimmune Diseases
- 1.4 Global Market Growth Prospects
- 1.5 Global Humanized Monoclonal Antibody Drugs Growth Trends by Region
- 1.5.1 Global Humanized Monoclonal Antibody Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Humanized Monoclonal Antibody Drugs Market Size by Region (2021-2026)
- 1.5.3 Humanized Monoclonal Antibody Drugs Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Humanized Monoclonal Antibody Drugs Market Dynamics
- 2.1 Humanized Monoclonal Antibody Drugs Industry Trends
- 2.2 Humanized Monoclonal Antibody Drugs Industry Drivers
- 2.3 Humanized Monoclonal Antibody Drugs Industry Opportunities and Challenges
- 2.4 Humanized Monoclonal Antibody Drugs Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Humanized Monoclonal Antibody Drugs Revenue by Company (2021-2026)
- 3.2 Global Humanized Monoclonal Antibody Drugs Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Humanized Monoclonal Antibody Drugs Key Company Head office and Area Served
- 3.4 Global Humanized Monoclonal Antibody Drugs Company, Product Type & Application
- 3.5 Global Humanized Monoclonal Antibody Drugs Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Humanized Monoclonal Antibody Drugs Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Humanized Monoclonal Antibody Drugs Players Market Share by Revenue in 2025
- 3.6.3 2025 Humanized Monoclonal Antibody Drugs Tier 1, Tier 2, and Tier 3
4 Humanized Monoclonal Antibody Drugs Market by Type
- 4.1 Global Humanized Monoclonal Antibody Drugs Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Humanized Monoclonal Antibody Drugs Market Size by Type (2021-2032)
- 4.3 Global Humanized Monoclonal Antibody Drugs Market Size Share by Type (2021-2032)
5 Humanized Monoclonal Antibody Drugs Market by Application
- 5.1 Global Humanized Monoclonal Antibody Drugs Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Humanized Monoclonal Antibody Drugs Market Size by Application (2021-2032)
- 5.3 Global Humanized Monoclonal Antibody Drugs Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Innovent Bio
- 6.1.1 Innovent Bio Company Information
- 6.1.2 Innovent Bio Business Overview
- 6.1.3 Innovent Bio Humanized Monoclonal Antibody Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Innovent Bio Humanized Monoclonal Antibody Drugs Product Portfolio
- 6.1.5 Innovent Bio Recent Developments
- 6.2 Takeda
- 6.2.1 Takeda Company Information
- 6.2.2 Takeda Business Overview
- 6.2.3 Takeda Humanized Monoclonal Antibody Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Takeda Humanized Monoclonal Antibody Drugs Product Portfolio
- 6.2.5 Takeda Recent Developments
- 6.3 Teva
- 6.3.1 Teva Company Information
- 6.3.2 Teva Business Overview
- 6.3.3 Teva Humanized Monoclonal Antibody Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Teva Humanized Monoclonal Antibody Drugs Product Portfolio
- 6.3.5 Teva Recent Developments
- 6.4 Sun Pharmaceutical
- 6.4.1 Sun Pharmaceutical Company Information
- 6.4.2 Sun Pharmaceutical Business Overview
- 6.4.3 Sun Pharmaceutical Humanized Monoclonal Antibody Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Sun Pharmaceutical Humanized Monoclonal Antibody Drugs Product Portfolio
- 6.4.5 Sun Pharmaceutical Recent Developments
- 6.5 Johnson & Johnson
- 6.5.1 Johnson & Johnson Company Information
- 6.5.2 Johnson & Johnson Business Overview
- 6.5.3 Johnson & Johnson Humanized Monoclonal Antibody Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Johnson & Johnson Humanized Monoclonal Antibody Drugs Product Portfolio
- 6.5.5 Johnson & Johnson Recent Developments
- 6.6 Qilu Pharma
- 6.6.1 Qilu Pharma Company Information
- 6.6.2 Qilu Pharma Business Overview
- 6.6.3 Qilu Pharma Humanized Monoclonal Antibody Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Qilu Pharma Humanized Monoclonal Antibody Drugs Product Portfolio
- 6.6.5 Qilu Pharma Recent Developments
- 6.7 Novartis
- 6.7.1 Novartis Company Information
- 6.7.2 Novartis Business Overview
- 6.7.3 Novartis Humanized Monoclonal Antibody Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Novartis Humanized Monoclonal Antibody Drugs Product Portfolio
- 6.7.5 Novartis Recent Developments
- 6.8 Merck & Co
- 6.8.1 Merck & Co Company Information
- 6.8.2 Merck & Co Business Overview
- 6.8.3 Merck & Co Humanized Monoclonal Antibody Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 Merck & Co Humanized Monoclonal Antibody Drugs Product Portfolio
- 6.8.5 Merck & Co Recent Developments
- 6.9 Roche
- 6.9.1 Roche Company Information
- 6.9.2 Roche Business Overview
- 6.9.3 Roche Humanized Monoclonal Antibody Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 Roche Humanized Monoclonal Antibody Drugs Product Portfolio
- 6.9.5 Roche Recent Developments
- 6.10 Eli Lilly & Co
- 6.10.1 Eli Lilly & Co Company Information
- 6.10.2 Eli Lilly & Co Business Overview
- 6.10.3 Eli Lilly & Co Humanized Monoclonal Antibody Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 Eli Lilly & Co Humanized Monoclonal Antibody Drugs Product Portfolio
- 6.10.5 Eli Lilly & Co Recent Developments
- 6.11 Pfizer
- 6.11.1 Pfizer Company Information
- 6.11.2 Pfizer Business Overview
- 6.11.3 Pfizer Humanized Monoclonal Antibody Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 Pfizer Humanized Monoclonal Antibody Drugs Product Portfolio
- 6.11.5 Pfizer Recent Developments
- 6.12 Beigene
- 6.12.1 Beigene Company Information
- 6.12.2 Beigene Business Overview
- 6.12.3 Beigene Humanized Monoclonal Antibody Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 Beigene Humanized Monoclonal Antibody Drugs Product Portfolio
- 6.12.5 Beigene Recent Developments
- 6.13 GlaxoSmithKline
- 6.13.1 GlaxoSmithKline Company Information
- 6.13.2 GlaxoSmithKline Business Overview
- 6.13.3 GlaxoSmithKline Humanized Monoclonal Antibody Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.13.4 GlaxoSmithKline Humanized Monoclonal Antibody Drugs Product Portfolio
- 6.13.5 GlaxoSmithKline Recent Developments
- 6.14 Biogen
- 6.14.1 Biogen Company Information
- 6.14.2 Biogen Business Overview
- 6.14.3 Biogen Humanized Monoclonal Antibody Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.14.4 Biogen Humanized Monoclonal Antibody Drugs Product Portfolio
- 6.14.5 Biogen Recent Developments
- 6.15 AbbVie
- 6.15.1 AbbVie Company Information
- 6.15.2 AbbVie Business Overview
- 6.15.3 AbbVie Humanized Monoclonal Antibody Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.15.4 AbbVie Humanized Monoclonal Antibody Drugs Product Portfolio
- 6.15.5 AbbVie Recent Developments
- 6.16 AstraZeneca
- 6.16.1 AstraZeneca Company Information
- 6.16.2 AstraZeneca Business Overview
- 6.16.3 AstraZeneca Humanized Monoclonal Antibody Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.16.4 AstraZeneca Humanized Monoclonal Antibody Drugs Product Portfolio
- 6.16.5 AstraZeneca Recent Developments
- 6.17 UCB
- 6.17.1 UCB Company Information
- 6.17.2 UCB Business Overview
- 6.17.3 UCB Humanized Monoclonal Antibody Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.17.4 UCB Humanized Monoclonal Antibody Drugs Product Portfolio
- 6.17.5 UCB Recent Developments
- 6.18 Gilead Sciences
- 6.18.1 Gilead Sciences Company Information
- 6.18.2 Gilead Sciences Business Overview
- 6.18.3 Gilead Sciences Humanized Monoclonal Antibody Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.18.4 Gilead Sciences Humanized Monoclonal Antibody Drugs Product Portfolio
- 6.18.5 Gilead Sciences Recent Developments
7 North America
- 7.1 North America Humanized Monoclonal Antibody Drugs Market Size (2021-2032)
- 7.2 North America Humanized Monoclonal Antibody Drugs Market Size by Type
- 7.2.1 North America Humanized Monoclonal Antibody Drugs Market Size by Type (2021-2026)
- 7.2.2 North America Humanized Monoclonal Antibody Drugs Market Size by Type (2027-2032)
- 7.2.3 North America Humanized Monoclonal Antibody Drugs Market Share by Type (2021-2032)
- 7.3 North America Humanized Monoclonal Antibody Drugs Market Size by Application
- 7.3.1 North America Humanized Monoclonal Antibody Drugs Market Size by Application (2021-2026)
- 7.3.2 North America Humanized Monoclonal Antibody Drugs Market Size by Application (2027-2032)
- 7.3.3 North America Humanized Monoclonal Antibody Drugs Market Share by Application (2021-2032)
- 7.4 North America Humanized Monoclonal Antibody Drugs Market Size by Country
- 7.4.1 North America Humanized Monoclonal Antibody Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Humanized Monoclonal Antibody Drugs Market Size by Country (2021-2026)
- 7.4.3 North America Humanized Monoclonal Antibody Drugs Market Size by Country (2027-2032)
- 7.4.4 North America Humanized Monoclonal Antibody Drugs Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Humanized Monoclonal Antibody Drugs Market Size (2021-2032)
- 8.2 Europe Humanized Monoclonal Antibody Drugs Market Size by Type
- 8.2.1 Europe Humanized Monoclonal Antibody Drugs Market Size by Type (2021-2026)
- 8.2.2 Europe Humanized Monoclonal Antibody Drugs Market Size by Type (2027-2032)
- 8.2.3 Europe Humanized Monoclonal Antibody Drugs Market Share by Type (2021-2032)
- 8.3 Europe Humanized Monoclonal Antibody Drugs Market Size by Application
- 8.3.1 Europe Humanized Monoclonal Antibody Drugs Market Size by Application (2021-2026)
- 8.3.2 Europe Humanized Monoclonal Antibody Drugs Market Size by Application (2027-2032)
- 8.3.3 Europe Humanized Monoclonal Antibody Drugs Market Share by Application (2021-2032)
- 8.4 Europe Humanized Monoclonal Antibody Drugs Market Size by Country
- 8.4.1 Europe Humanized Monoclonal Antibody Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Humanized Monoclonal Antibody Drugs Market Size by Country (2021-2026)
- 8.4.3 Europe Humanized Monoclonal Antibody Drugs Market Size by Country (2027-2032)
- 8.4.4 Europe Humanized Monoclonal Antibody Drugs Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Humanized Monoclonal Antibody Drugs Market Size (2021-2032)
- 9.2 China Humanized Monoclonal Antibody Drugs Market Size by Type
- 9.2.1 China Humanized Monoclonal Antibody Drugs Market Size by Type (2021-2026)
- 9.2.2 China Humanized Monoclonal Antibody Drugs Market Size by Type (2027-2032)
- 9.2.3 China Humanized Monoclonal Antibody Drugs Market Share by Type (2021-2032)
- 9.3 China Humanized Monoclonal Antibody Drugs Market Size by Application
- 9.3.1 China Humanized Monoclonal Antibody Drugs Market Size by Application (2021-2026)
- 9.3.2 China Humanized Monoclonal Antibody Drugs Market Size by Application (2027-2032)
- 9.3.3 China Humanized Monoclonal Antibody Drugs Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Humanized Monoclonal Antibody Drugs Market Size (2021-2032)
- 10.2 Asia Humanized Monoclonal Antibody Drugs Market Size by Type
- 10.2.1 Asia Humanized Monoclonal Antibody Drugs Market Size by Type (2021-2026)
- 10.2.2 Asia Humanized Monoclonal Antibody Drugs Market Size by Type (2027-2032)
- 10.2.3 Asia Humanized Monoclonal Antibody Drugs Market Share by Type (2021-2032)
- 10.3 Asia Humanized Monoclonal Antibody Drugs Market Size by Application
- 10.3.1 Asia Humanized Monoclonal Antibody Drugs Market Size by Application (2021-2026)
- 10.3.2 Asia Humanized Monoclonal Antibody Drugs Market Size by Application (2027-2032)
- 10.3.3 Asia Humanized Monoclonal Antibody Drugs Market Share by Application (2021-2032)
- 10.4 Asia Humanized Monoclonal Antibody Drugs Market Size by Country
- 10.4.1 Asia Humanized Monoclonal Antibody Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Humanized Monoclonal Antibody Drugs Market Size by Country (2021-2026)
- 10.4.3 Asia Humanized Monoclonal Antibody Drugs Market Size by Country (2027-2032)
- 10.4.4 Asia Humanized Monoclonal Antibody Drugs Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Humanized Monoclonal Antibody Drugs Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Humanized Monoclonal Antibody Drugs Market Size by Type
- 11.2.1 South America, Middle East & Africa Humanized Monoclonal Antibody Drugs Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Humanized Monoclonal Antibody Drugs Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Humanized Monoclonal Antibody Drugs Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Humanized Monoclonal Antibody Drugs Market Size by Application
- 11.3.1 South America, Middle East & Africa Humanized Monoclonal Antibody Drugs Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Humanized Monoclonal Antibody Drugs Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Humanized Monoclonal Antibody Drugs Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Humanized Monoclonal Antibody Drugs Market Size by Country
- 11.4.1 South America, Middle East & Africa Humanized Monoclonal Antibody Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Humanized Monoclonal Antibody Drugs Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Humanized Monoclonal Antibody Drugs Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Humanized Monoclonal Antibody Drugs Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$3,950USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst